CEOs, Senior Executives Highlight Expansions at the DCAT Member Company Announcement Forum

CEOs and senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week.

CEOs and senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week.

By Patricia Van Arnum, Editorial Director, DCAT, pvanarnum@dcat.org 

CEO and senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week, the flagship event of the Drug, Chemical & Associated Technologies Association (DCAT) and the premier event for the global bio/pharmaceutical business ecosystem. Companies reported the latest in expansion plans across the bio/pharmaceutical value chain: from drug substances (small-molecules and biologics) to drug products (solid dosage and injectable product forms) and packaging. In all, 20 companies took to the podium to make their announcements. The program kicked off DCAT Week on Monday March 23, 2026. 

Details of each company’s announcement can be found below. 

Recent Feature Articles

China: The Innovation Factor Coming Into Play

By
Pfizer’s $10.5-billion partnering deal with China’s Innovent Biologics is the latest deal between the bio/pharmaceutical majors and China-based innovator drug companies. Is China becoming a force in innovation?

Oncology Drug Market: The Ups and Downs 

By
ASCO’s Annual Meeting, held this week in Chicago, is when bio/pharma companies highlight the most promising in their cancer drug pipelines and portfolios. What is the outlook for the global oncology drug market?

Lilly Continues Biotech Acquisition Spree

By
Lilly has been active on the M&A front with a series of biotech acquisitions totaling up to more than $20 billion in 2026 to date  What moves is the company making?

Shoring up API Mfg & Supply in Europe

By
European policymakers reached a provisional agreement on the Critical Medicines Act, designed to strengthen the EU’s pharma manufacturing base. What is next?